Dihydrotestosterone (DHT) and Bottom Growth
Dihydrotestosterone (DHT) is a potent androgen hormone that plays a significant role in the development of male characteristics. For transgender men (trans men) and non-binary individuals assigned female at birth who undergo hormone therapy with testosterone, DHT can lead to various changes in the body. One of these changes is "bottom growth", which refers to the enlargement of the clitoris, making it more similar to a small penis in size and function.
When testosterone is administered as part of hormone replacement therapy (HRT), it is partially converted into DHT by the enzyme 5-alpha reductase. DHT is more potent than testosterone in binding to androgen receptors and promoting the development of male secondary sexual characteristics.
Under the influence of DHT, the clitoral tissue can enlarge and elongate. This growth varies significantly among individuals, with some experiencing more noticeable changes than others.
Bottom growth typically begins within a few months of starting testosterone therapy, with the most significant changes occurring in the first year. However, growth can continue at a slower rate for several years.
The clitoris may become more sensitive during the initial stages of growth. This increased sensitivity can be uncomfortable for some individuals but often stabilises over time. The clitoris may develop a more phallic appearance and can become erect when aroused. This change can enhance sexual pleasure for some individuals.
Related Articles
Understanding Bottom Growth in Transmasculine Individuals
Introduction "Bottom growth" refers to the physical changes experienced by transmasculine individuals during masculinising hormone therapy, particularly the growth of the clitoris. In the process of masculinization, bottom growth can be a significant ...
Skeletal Growth and Masculinisation
The effects of masculinisation through hormone therapy, particularly testosterone, on the skeleton can vary depending on several factors, including age and the timing of treatment in relation to the closure of growth plates (epiphyseal plates) in the ...
Maximising Breast Growth: Factors, Hormone Therapy, and Alternatives
Introduction Breast growth, especially in the context of gender-affirming care for transgender women and non-binary individuals, involves a multidimensional approach. Understanding the factors influencing breast development and exploring options like ...
Finasteride - administration
Finasteride is a medication commonly used in gender-affirming care for transgender women. It is a 5-alpha-reductase inhibitor that works by blocking the conversion of testosterone to dihydrotestosterone (DHT), a potent form of male sex hormone. ...
Finasteride in Gender-Affirming Care: An overview
Introduction Gender-affirming care encompasses various medical interventions aimed at aligning an individual’s physical characteristics with their gender identity. Among these interventions, finasteride, a medication primarily used to treat benign ...